BioToxTech Co

BioToxTech Co Long-term Debt

The Long-Term Debt of BioToxTech Co (086040.KQ) as of Nov 12, 2026 is 11.25 B KRW. In the previous year, Long-Term Debt was 16.32 B KRW — a change of -31.05% (lower).

Long-term Debt

11.25 BKRW

YoY

-31.05%

Last updated:

Long-Term Debt of BioToxTech Co is 2025 11.25 B KRW. Long-Term Debt of BioToxTech Co was 2024 16.32 B KRW. It decreases by -31.05% lower compared to the previous year.

The BioToxTech Co Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2018
1.50 B KRW
Jan 1, 2019
5.94 B KRW
Jan 1, 2020
2.93 B KRW
Jan 1, 2021
2.01 B KRW
Jan 1, 2022
20.14 B KRW
Jan 1, 2023
20.19 B KRW
Jan 1, 2024
16.32 B KRW
Jan 1, 2025
11.25 B KRW
The BioToxTech Co Long-term Debt history
YEARLong-term DebtYoY
11.25 BKRW-31.05%
16.32 BKRW-19.20%
20.19 BKRW+0.27%
20.14 BKRW+903.63%
2.01 BKRW-31.44%
2.93 BKRW-50.71%
5.94 BKRW+295.84%
1.50 BKRW+150.00%
600.00 MKRW—
0.00KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

Long-Term Debt of BioToxTech Co is 11.25 B KRW in 2025.

Long-Term Debt of BioToxTech Co changed from 16.32 B KRW to 11.25 B KRW, representing a -31.05% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's BioToxTech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — BioToxTech Co

All Key Metrics — BioToxTech Co